The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir

Young, Jim; Wang, Qing; Fux, Christoph Andreas; Bernasconi, Enos; Furrer, Hansjakob; Vernazza, Pietro; Calmy, A.; Cavassini, Matthias; Weber, Rainer; Battegay, Manuel; Bucher, Heiner C; Swiss HIV Cohort, Study (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV medicine, 15(8), pp. 505-510. Blackwell Science 10.1111/hiv.12149

Preview	Text SHCS_730_Short_Report_HIVMed_revised.pdf - Accepted Version Available under License Publisher holds Copyright. Download (45kB) | Preview
	Text hiv12149.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (72kB)

OBJECTIVES
Tenofovir is associated with reduced renal function. It is not clear whether patients can be expected to fully recover their renal function if tenofovir is discontinued.

METHODS
We calculated the estimated glomerular filtration rate (eGFR) for patients in the Swiss HIV Cohort Study remaining on tenofovir for at least 1 year after starting a first antiretroviral therapy regimen with tenofovir and either efavirenz or the ritonavir-boosted protease inhibitor lopinavir, atazanavir or darunavir. We estimated the difference in eGFR slope between those who discontinued tenofovir after 1 year and those who remained on tenofovir.

RESULTS
A total of 1049 patients on tenofovir for at least 1 year were then followed for a median of 26 months, during which time 259 patients (25%) discontinued tenofovir. After 1 year on tenofovir, the difference in eGFR between those starting with efavirenz and those starting with lopinavir, atazanavir and darunavir was - 0.7 [95% confidence interval (CI) -2.3 to 0.8], -1.4 (95% CI -3.2 to 0.3) and 0.0 (95% CI -1.7 to 1.7) mL/min/1.73 m(2) , respectively. The estimated linear rate of decline in eGFR on tenofovir was -1.1 (95% CI -1.5 to -0.8) mL/min/1.73 m(2) per year and its recovery after discontinuing tenofovir was 2.1 (95% CI 1.3 to 2.9) mL/min/1.73 m(2) per year. Patients starting tenofovir with either lopinavir or atazanavir appeared to have the same rates of decline and recovery as those starting tenofovir with efavirenz.

CONCLUSIONS
If patients discontinue tenofovir, clinicians can expect renal function to recover more rapidly than it declined.

Interest & Impact

Downloads

440 since deposited on 01 Apr 2014
27 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item